March 19, 2018 / 12:31 PM / a month ago

BRIEF-Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met

March 19 (Reuters) - Aclaris Therapeutics Inc:

* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS

* ACLARIS THERAPEUTICS INC - PRIMARY, SECONDARY, AND EXPLORATORY ENDPOINTS OF PHASE 2 TRIAL MET DURING 8-WEEK TREATMENT PERIOD

* ACLARIS THERAPEUTICS - AFTER TREATMENT COMPLETED, GREATER IMPROVEMENT VERSUS. PLACEBO OBSERVED IN 3-MONTH POST-TREATMENT FOLLOW-UP EVALUATION IN TRIAL

* ACLARIS THERAPEUTICS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AMONG SUBJECTS TREATED WITH A-101 45%

* ACLARIS THERAPEUTICS INC - A-101 45% WAS GENERALLY WELL TOLERATED THROUGH VISIT 13 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below